{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:33:36Z","timestamp":1792100016248,"version":"4.4.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008563","name":"Fondazione Ettore e Valeria Rossi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008563","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00302","type":"journal-article","created":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:20:02Z","timestamp":1520900402000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":272,"title":["The Immunomodulatory Effects of Macrolides\u2014A Systematic Review of the Underlying Mechanisms"],"prefix":"10.3389","volume":"9","author":[{"given":"Petra","family":"Zimmermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria C.","family":"Ziesenitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"B1","first-page":"137","article-title":"Clarithromycin and azithromycin: new macrolide antibiotics","volume":"11","author":"Piscitelli","year":"1992","journal-title":"Clin Pharm"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","article-title":"Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms","volume":"31","author":"Retsema","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.idc.2004.04.010","article-title":"Macrolides and ketolides: azithromycin, clarithromycin, telithromycin","volume":"18","author":"Zuckerman","year":"2004","journal-title":"Infect Dis Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0022-2836(03)00662-4","article-title":"The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome","volume":"330","author":"Tenson","year":"2003","journal-title":"J Mol Biol"},{"key":"B5","first-page":"83","article-title":"[Content of monomycin in bile and its effectiveness in inflammatory diseases and surgery of the biliary tract]","volume":"8","author":"Poliak","year":"1963","journal-title":"Antibiotiki"},{"key":"B6","first-page":"29","article-title":"[Use of erythromycin in non-specific inflammatory diseases of the Urogenital System]","volume":"28","author":"Parfenova","year":"1963","journal-title":"Urol Mosc"},{"key":"B7","first-page":"450","article-title":"[Erythromycin ointment therapy of inflammatory diseases of eyelid, conjunctiva and cornea. (Clinico-Experimental Studies)]","volume":"19","author":"Gluzman","year":"1964","journal-title":"Oftalmol Zh"},{"key":"B8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/1523-1747.ep12610281","article-title":"Anti-inflammatory effects of antimicrobial agents: an in vivo study","volume":"65","author":"Plewig","year":"1975","journal-title":"J Invest Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1164\/ajrccm.157.6.9710075","article-title":"Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin","volume":"157","author":"Kudoh","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3122\/jabfm.2012.04.110309","article-title":"Azithromycin for bronchial asthma in adults: an effectiveness trial","volume":"25","author":"Hahn","year":"2012","journal-title":"J Am Board Fam Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1399-3038.2012.01280.x","article-title":"Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study","volume":"23","author":"Koutsoubari","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"key":"B13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1756-185X.2009.01379.x","article-title":"A double blind, randomized, placebo controlled study to evaluate the efficacy of erythromycin in patients with knee effusion due to osteoarthritis","volume":"12","author":"Sadreddini","year":"2009","journal-title":"Int J Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jamaophthalmol.2015.2326","article-title":"Effects of azithromycin on gene expression profiles of proinflammatory and anti-inflammatory mediators in the eyelid margin and conjunctiva of patients with meibomian gland disease","volume":"133","author":"Zhang","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1177\/0022034510368650","article-title":"Azithromycin decreases crevicular fluid volume and mediator content","volume":"89","author":"Ho","year":"2010","journal-title":"J Dent Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/jre.12123","article-title":"Effect of adjunctive roxithromycin therapy on interleukin-1beta, transforming growth factor-beta1 and vascular endothelial growth factor in gingival crevicular fluid of cyclosporine A-treated patients with gingival overgrowth","volume":"49","author":"Gong","year":"2014","journal-title":"J Periodontal Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1017\/S0022215112000485","article-title":"Effect of long-term, low-dose clarithromycin on T helper 2 cytokines, eosinophilic cationic protein and the \u2018regulated on activation, normal T cell expressed and secreted\u2019 chemokine in the nasal secretions of patients with nasal polyposis","volume":"126","author":"Peric","year":"2012","journal-title":"J Laryngol Otol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5507\/bp.2010.049","article-title":"Influence of allergy on the immunomodulatory and clinical effects of long-term low-dose macrolide treatment of nasal polyposis","volume":"154","author":"Peric","year":"2010","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"B21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2500\/105065800782102717","article-title":"Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage","volume":"14","author":"Yamada","year":"2000","journal-title":"Am J Rhinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF02852391","article-title":"Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa","volume":"18","author":"MacLeod","year":"2001","journal-title":"Adv Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1475-097X.2008.00848.x","article-title":"Effects of long-term clarithromycin treatment on lavage-fluid markers of inflammation in chronic rhinosinusitis","volume":"29","author":"Cervin","year":"2009","journal-title":"Clin Physiol Funct Imaging"},{"key":"B24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00005537-200402000-00019","article-title":"Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis","volume":"114","author":"Wallwork","year":"2004","journal-title":"Laryngoscope"},{"key":"B25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1620\/tjem.182.115","article-title":"Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients","volume":"182","author":"Suzuki","year":"1997","journal-title":"Tohoku J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/01.mlg.0000191560.53555.08","article-title":"A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis","volume":"116","author":"Wallwork","year":"2006","journal-title":"Laryngoscope"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1183\/09031936.00093913","article-title":"Randomised controlled trial of azithromycin in smokers with asthma","volume":"42","author":"Cameron","year":"2013","journal-title":"Eur Respir J"},{"key":"B28","first-page":"719","article-title":"Clinical impacts of azithromycin on lung function and cytokines for athmatic patients","volume":"36","author":"He","year":"2009","journal-title":"JMS"},{"key":"B29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2500\/aap.2007.28.2958","article-title":"Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report","volume":"28","author":"Piacentini","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1081-1206(10)60935-0","article-title":"Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial","volume":"97","author":"Fonseca-Aten","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S1081-1206(10)62409-X","article-title":"Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma","volume":"84","author":"Amayasu","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1378\/chest.121.6.1782","article-title":"Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin","volume":"121","author":"Kraft","year":"2002","journal-title":"Chest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1164\/rccm.200707-1134OC","article-title":"Clarithromycin targets neutrophilic airway inflammation in refractory asthma","volume":"177","author":"Simpson","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"B34","first-page":"1948","article-title":"Effect of clarithromycin on non-eosinophilic refractory asthma","volume":"17","author":"Wang","year":"2012","journal-title":"J Clin Pulm Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1046\/j.1365-2222.1999.00551.x","article-title":"Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma","volume":"29","author":"Shoji","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3109\/02770909509089507","article-title":"The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma","volume":"32","author":"Kamoi","year":"1995","journal-title":"J Asthma"},{"key":"B37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00408-014-9619-0","article-title":"Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients","volume":"192","author":"Fouka","year":"2014","journal-title":"Lung"},{"key":"B38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2710.2006.00708.x","article-title":"Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis","volume":"31","author":"Yal\u00e7in","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"708608","DOI":"10.1155\/2014\/708608","article-title":"Effect of low-dose, long-term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis","volume":"2014","author":"Liu","year":"2014","journal-title":"Mediators Inflamm"},{"key":"B40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejphar.2005.05.023","article-title":"Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment","volume":"517","author":"Parnham","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00151829-200403010-00007","article-title":"The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial","volume":"3","author":"Banerjee","year":"2004","journal-title":"Treat Respir Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000321374","article-title":"Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease","volume":"80","author":"He","year":"2010","journal-title":"Respiration"},{"key":"B43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bbrc.2004.09.018","article-title":"The effect of long-term treatment with erythromycin on Th1 and Th2 cytokines in diffuse panbronchiolitis","volume":"324","author":"Park","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1378\/chest.106.4.1116","article-title":"Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis","volume":"106","author":"Oda","year":"1994","journal-title":"Chest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1164\/ajrccm\/147.1.153","article-title":"A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis","volume":"147","author":"Kadota","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2739\/kurumemedj.43.279","article-title":"Neutrophil chemotactic activity in bronchoalveolar lavage fluid recovered from patients with diffuse panbronchiolitis","volume":"43","author":"Katsuki","year":"1996","journal-title":"Kurume Med J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1164\/ajrccm\/146.1.196","article-title":"Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients","volume":"146","author":"Ichikawa","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000196514","article-title":"Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy","volume":"63","author":"Sakito","year":"1996","journal-title":"Respiration"},{"key":"B49","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1378\/chest.104.4.1191","article-title":"Anti-inflammatory action of erythromycin. Its inhibitory effect on neutrophil NADPH oxidase activity","volume":"104","author":"Umeki","year":"1993","journal-title":"Chest"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1378\/chest.12-0628","article-title":"Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa","volume":"142","author":"Ratjen","year":"2012","journal-title":"Chest"},{"key":"B51","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"key":"B52","first-page":"416","article-title":"Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status","volume":"51","author":"Do\u011fru","year":"2009","journal-title":"Turk J Pediatr"},{"key":"B53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/09629350410001688495","article-title":"Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease","volume":"13","author":"Pukhalsky","year":"2004","journal-title":"Mediators Inflamm"},{"key":"B54","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.trim.2011.06.006","article-title":"Azithromycin decreases MMP-9 expression in the airways of lung transplant recipients","volume":"25","author":"Verleden","year":"2011","journal-title":"Transpl Immunol"},{"key":"B55","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/CDLI.10.4.525-528.2003","article-title":"Effect of clarithromycin on inflammatory markers in patients with atherosclerosis","volume":"10","author":"Berg","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Culi\u0107","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1034\/j.1399-3003.2000.15e08.x","article-title":"Effects of azithromycin on ozone-induced airway neutrophilia and cytokine release","volume":"15","author":"Criqui","year":"2000","journal-title":"Eur Respir J"},{"key":"B58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1006\/pupt.1998.0123","article-title":"Function of human alveolar macrophages after a 3-day course of azithromycin in healthy volunteers","volume":"11","author":"Aubert","year":"1998","journal-title":"Pulm Pharmacol Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1067\/mhn.2002.124849","article-title":"One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effects on mucociliary parameters and nasal nitric oxide","volume":"126","author":"Cervin","year":"2002","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B60","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10157-010-0357-1","article-title":"Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients","volume":"15","author":"Tone","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1600-0765.1998.tb02349.x","article-title":"Vascular endothelial growth factor in human periodontal disease","volume":"33","author":"Booth","year":"1998","journal-title":"J Periodontal Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000027731","article-title":"Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy","volume":"62","author":"Suzuki","year":"2000","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"B63","doi-asserted-by":"publisher","first-page":"209","DOI":"10.11150\/kansenshogakuzasshi1970.68.209","article-title":"[Mechanism of efficacy of erythromycin on diffuse panbronchiolitis \u2013 effect of erythromycin on cytokine mRNA expression in human whole blood model]","volume":"68","author":"Akiyoshi","year":"1994","journal-title":"Kansenshogaku Zasshi"},{"key":"B64","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.intimp.2010.12.010","article-title":"Azithromycin inhibits macrophage interleukin-1beta production through inhibition of activator protein-1 in lipopolysaccharide-induced murine pulmonary neutrophilia","volume":"11","author":"Bosnar","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/09273940903359725","article-title":"Anti-inflammatory activity of azithromycin as measured by its NF-kappaB, inhibitory activity","volume":"18","author":"Cheung","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"B66","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.bbrc.2006.09.132","article-title":"Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells","volume":"350","author":"Cigana","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000350828","article-title":"Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis","volume":"86","author":"Yao","year":"2013","journal-title":"Respiration"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.rmed.2013.05.004","article-title":"A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease","volume":"107","author":"Donath","year":"2013","journal-title":"Respir Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"Cd002203","DOI":"10.1002\/14651858.CD002203.pub4","article-title":"Macrolide antibiotics for cystic fibrosis","volume":"11","author":"Southern","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B70","doi-asserted-by":"publisher","first-page":"Cd010337","DOI":"10.1002\/14651858.CD010337.pub2","article-title":"Interventions for bronchiectasis: an overview of Cochrane systematic reviews","volume":"7","author":"Welsh","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B71","doi-asserted-by":"publisher","first-page":"Cd002997","DOI":"10.1002\/14651858.CD002997.pub4","article-title":"Macrolides for chronic asthma","volume":"9","author":"Kew","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B72","doi-asserted-by":"publisher","first-page":"Cd007716","DOI":"10.1002\/14651858.CD007716.pub3","article-title":"Macrolides for diffuse panbronchiolitis","volume":"2","author":"Yang","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","article-title":"Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial","volume":"68","author":"Brusselle","year":"2013","journal-title":"Thorax"},{"key":"B74","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2004.03.011","article-title":"Roxithromycin downmodulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells: its dual inhibitory effects on the ligands and the receptors","volume":"228","author":"Kobayashi","year":"2004","journal-title":"Cell Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s10753-011-9305-9","article-title":"Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity","volume":"35","author":"Iveti\u0107 Tkal\u010devi\u0107","year":"2012","journal-title":"Inflammation"},{"key":"B76","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/ppul.21613","article-title":"Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial","volume":"47","author":"Robinson","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jdermsci.2009.01.007","article-title":"Roxithromycin inhibits chemokine-induced chemotaxis of Th1 and Th2 cells but regulatory T cells","volume":"54","author":"Ito","year":"2009","journal-title":"J Dermatol Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.plefa.2006.12.005","article-title":"Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production","volume":"76","author":"Sato","year":"2007","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"B80","doi-asserted-by":"publisher","first-page":"12016","DOI":"10.1038\/srep12016","article-title":"Azithromycin inhibits IL-1 secretion and non-canonical inflammasome activation","volume":"5","author":"Gualdoni","year":"2015","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00003088-199937050-00003","article-title":"Clinical pharmacokinetics of clarithromycin","volume":"37","author":"Rodvold","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"B82","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"B83","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/jac\/27.suppl_A.61","article-title":"The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans","volume":"27","author":"Fraschini","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"B84","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF01641314","article-title":"[Tissue penetration of erythromycin (author\u2019s transl)]","volume":"7","author":"Dette","year":"1979","journal-title":"Infection"},{"key":"B85","doi-asserted-by":"publisher","first-page":"5s","DOI":"10.1016\/0002-9343(91)90394-D","article-title":"Tissue-directed pharmacokinetics","volume":"91","author":"Schentag","year":"1991","journal-title":"Am J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00302\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T02:40:04Z","timestamp":1603939204000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00302\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":85,"alternative-id":["10.3389\/fimmu.2018.00302"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00302","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,13]]},"article-number":"302"}}